Last updated on January 2020

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive HER2 Negative Luminal Breast Cancer.


Brief description of study

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.

Detailed Study Description

Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients are either advised to continue letrozole treatment (if Ki67 <1%) or will be randomized between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if Ki67 1%).

Clinical Study Identifier: NCT03283384

Find a site near you

Start Over

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands
  Connect »

Ziekenhuis Amstelland

Amstelveen, Netherlands
  Connect »

Gelre Ziekenhuizen

Apeldoorn, Netherlands
  Connect »

HAGA Ziekenhuis

Den Haag, Netherlands
  Connect »

Catharina Ziekenhuis

Eindhoven, Netherlands
  Connect »

Maxima Medisch Centrum

Eindhoven, Netherlands
  Connect »

Spaarne Gasthuis

Haarlem, Netherlands
  Connect »

Ziekenhuis St. Jansdal

Harderwijk, Netherlands
  Connect »

Tergooi Ziekenhuizen

Hilversum, Netherlands
  Connect »

Laurentius Ziekenhuis

Roermond, Netherlands
  Connect »

Bravis Ziekenhuis

Roosendaal, Netherlands
  Connect »

Isala

Zwolle, Netherlands
  Connect »